Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgens can cause the growth of prostate cancer cells. IL-6 is expressed by prostate cancer and within the tumor microenvironment and shown to enhance prostate cancer and disease progression. Treatment with an anti-IL-6 a

Trial Details

NCT ID

NCT03821246

Phase

PHASE2

Sponsor

David Oh

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Atezolizumab
Tocilizumab
Etrumadenant

Locations (sample)

San Francisco, California, United States|37.77493,-122.41942
St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

Histologically confirmed adenocarcinoma of the prostate.
a. Subjects with small cell or neuroendocrine PC are not eligible.
Eligible for radical prostatectomy as determined by urologic oncology surgeon, and subject consents to proceeding with radical prostatectomy.
a. Deemed by urologic oncology surgeon to be appropriate for a "window-of-opportunity"study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →